Reenaers C, Cremer A, Dewit O, De Vroey B, Van Moerkercke W, Bossuyt P, Muls V, Imschoot J, Block S, Hantson A, Van Hootegem P
Centre Hospitalier Universitaire de Liège, Avenue de l'Hôpital 1, 4000 Liège, Belgium.
Cliniques Universitaires de Bruxelles, Hôpital Erasme, Brussels, Belgium.
Acta Gastroenterol Belg. 2020 Jan-Mar;83(1):15-23.
Vedolizumab (VDZ) is a gutselective integrin inhibitor used to treat Crohn's disease (CD) and ulcerative colitis (UC). This retrospective study assessed effectiveness and treatment persistence of VDZ in a Belgian reallife cohort of CD and UC patients.
CD and UC patients from 15 Belgian centers, who started VDZ between 01/09/2015 and 31/06/2016 and attended ≥1 visit after the first VDZ infusion, were included. Data were collected before first infusion, at week (W)10, W14 (CD patients only), month (M)6 and last follow-up. Treatment response and remission rates (changes in disease activity scores) and treatment persistence (Kaplan-Meier analysis) were assessed.
Of the 348 patients receiving at least one dose of VDZ, 325 (202 CD, 45 biologic-naïve; and 123 UC, 42 biologic-naïve) patients were included in data analyses. At M6, 87.6% (176/201) of CD and 86.1% (105/122) of UC patients were still on VDZ treatment, 75.6% (34/45) and 83.9% (26/31) achieved clinical response, and 66.7% (44/66) and 42.9% (15/35) were in remission. At M6 remission rates was significantly higher while response rates tended to be higher among biologic-naïve versus biologic-failure CD patients.
VDZ offers an effective treatment option in real-life settings and treatment effectiveness appears higher in biologic-naïve versus biologic-failure CD patients. (Acta gastroenterol. belg., 2020, 83, 15-23).
维多珠单抗（VDZ）是一种肠道选择性整合素抑制剂，用于治疗克罗恩病（CD）和溃疡性结肠炎（UC）。这项回顾性研究评估了VDZ在比利时CD和UC患者真实队列中的有效性和治疗持续性。
纳入来自比利时15个中心的CD和UC患者，这些患者在2015年9月1日至2016年6月31日期间开始使用VDZ，并在首次输注VDZ后至少就诊1次。在首次输注前、第10周、第14周（仅CD患者）、第6个月和最后一次随访时收集数据。评估治疗反应和缓解率（疾病活动评分变化）以及治疗持续性（Kaplan-Meier分析）。
在348例接受至少一剂VDZ的患者中，325例（202例CD，45例初治生物制剂患者；123例UC，42例初治生物制剂患者）纳入数据分析。在第6个月时，87.6%（176/201）的CD患者和86.1%（105/122）的UC患者仍在接受VDZ治疗，75.6%（34/45）和83.9%（26/31）达到临床反应，66.7%（44/66）和42.9%（15/35）处于缓解状态。在第6个月时，初治生物制剂患者的缓解率显著更高，而CD初治生物制剂患者的反应率往往更高。
在真实环境中，VDZ提供了一种有效的治疗选择，并且初治生物制剂患者的治疗效果似乎高于生物制剂治疗失败的CD患者。（《比利时胃肠病学学报》，2020年，83卷，15 - 23页）
